NF-κB Inhibitor, SN50 for cell activation

This peptide contains the nuclear localization sequence (NLS residues 360-369) of the transcription factor NF-κB p50 linked to a peptide cell-permeablization sequence, the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). SN50 inhibits translocation of the NF-κB active complex into the nucleus. In mouse endothelial LE-II cells induced with LPS, inhibition of NF-κB nuclear translocation was 88% at 50 µg/ml (18 µM). In human monocytic THP-1 cells induced by LPS or TNFα there was 85% inhibition at 100 µg/ml.

Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH

213546-53-3

2781.5

Biochemicals

SN50; AAVALLPAVLLALLAPVQRKRQKLMP

C₁₂₉H₂₃₀N₃₆O₂₉S

Lyophilized solid

N/A

TFA salt

Yes

≥97% by HPLC

H₂O

-20°C

Gel pack

24 months

Protect from air and moisture

cell

For cells, cell lines and tissues in culture till half confluency.Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.